Literature DB >> 23159056

Mycobacterium tuberculosis-driven targeted recalibration of macrophage lipid homeostasis promotes the foamy phenotype.

Varshneya Singh1, Shilpa Jamwal, Ritu Jain, Priyanka Verma, Rajesh Gokhale, Kanury V S Rao.   

Abstract

Upon infection, Mycobacterium tuberculosis (Mtb) metabolically alters the macrophage to create a niche that is ideally suited to its persistent lifestyle. Infected macrophages acquire a "foamy" phenotype characterized by the accumulation of lipid bodies (LBs), which serve as both a source of nutrients and a secure niche for the bacterium. While the functional significance of the foamy phenotype is appreciated, the biochemical pathways mediating this process are understudied. We found that Mtb induces the foamy phenotype via targeted manipulation of host cellular metabolism to divert the glycolytic pathway toward ketone body synthesis. This dysregulation enabled feedback activation of the anti-lipolytic G protein-coupled receptor GPR109A, leading to perturbations in lipid homeostasis and consequent accumulation of LBs in the macrophage. ESAT-6, a secreted Mtb virulence factor, mediates the enforcement of this feedback loop. Finally, we demonstrate that pharmacological targeting of pathways mediating this host-pathogen metabolic crosstalk provides a potential strategy for developing tuberculosis chemotherapy.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23159056     DOI: 10.1016/j.chom.2012.09.012

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  111 in total

1.  HIF-1α Is an Essential Mediator of IFN-γ-Dependent Immunity to Mycobacterium tuberculosis.

Authors:  Jonathan Braverman; Kimberly M Sogi; Daniel Benjamin; Daniel K Nomura; Sarah A Stanley
Journal:  J Immunol       Date:  2016-07-18       Impact factor: 5.422

Review 2.  The Minimal Unit of Infection: Mycobacterium tuberculosis in the Macrophage.

Authors:  Brian C VanderVen; Lu Huang; Kyle H Rohde; David G Russell
Journal:  Microbiol Spectr       Date:  2016-12

Review 3.  Are reactive oxygen species always detrimental to pathogens?

Authors:  Claudia N Paiva; Marcelo T Bozza
Journal:  Antioxid Redox Signal       Date:  2013-10-26       Impact factor: 8.401

4.  Disconnecting in vitro ESX-1 secretion from mycobacterial virulence.

Authors:  Patricia A DiGiuseppe Champion
Journal:  J Bacteriol       Date:  2013-10-11       Impact factor: 3.490

Review 5.  Host-directed therapeutics for tuberculosis: can we harness the host?

Authors:  Thomas R Hawn; Alastair I Matheson; Stephen N Maley; Omar Vandal
Journal:  Microbiol Mol Biol Rev       Date:  2013-12       Impact factor: 11.056

6.  Simvastatin increases the in vivo activity of the first-line tuberculosis regimen.

Authors:  Ciaran Skerry; Michael L Pinn; Natalie Bruiners; Richard Pine; Maria L Gennaro; Petros C Karakousis
Journal:  J Antimicrob Chemother       Date:  2014-05-22       Impact factor: 5.790

7.  Mycolates of Mycobacterium tuberculosis modulate the flow of cholesterol for bacillary proliferation in murine macrophages.

Authors:  Ilke Vermeulen; Mark Baird; Juma Al-Dulayymi; Muriel Smet; Jan Verschoor; Johan Grooten
Journal:  J Lipid Res       Date:  2017-02-13       Impact factor: 5.922

Review 8.  Immunologic manifestations of autophagy.

Authors:  Vojo Deretic; Tomonori Kimura; Graham Timmins; Pope Moseley; Santosh Chauhan; Michael Mandell
Journal:  J Clin Invest       Date:  2015-01-02       Impact factor: 14.808

9.  Infection of macrophages with Mycobacterium tuberculosis induces global modifications to phagosomal function.

Authors:  Maria Podinovskaia; Wonsik Lee; Shannon Caldwell; David G Russell
Journal:  Cell Microbiol       Date:  2013-01-09       Impact factor: 3.715

10.  PPAR-γ and Akt regulate GLUT1 and GLUT3 surface localization during Mycobacterium tuberculosis infection.

Authors:  Shyamashree Dasgupta; Ramesh Chandra Rai
Journal:  Mol Cell Biochem       Date:  2017-08-29       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.